Smith+Nephew Expands Robotic Surgery Portfolio with CORI SHOULDER Launch
Event summary
- Smith+Nephew debuts CORI SHOULDER robotic system for shoulder arthroplasty at AAOS 2026, marking its first commercial cases performed at Duke Health.
- Company expands trauma portfolio with EVOS PELVIC System launch and TRIGEN MAX Tibia Nailing System enhancements.
- Introduces end-to-end ASC development solutions through new strategic partnerships.
- 2025 revenue reached $6.2 billion, positioning Smith+Nephew as a major player in orthopedic technology.
The big picture
Smith+Nephew's expansion of its robotic surgery portfolio and trauma solutions underscores the industry shift toward precision orthopedics. The company's strategic partnerships for ASC development reflect broader trends in outpatient care expansion. With $6.2 billion in 2025 revenue, Smith+Nephew is well-positioned to capitalize on these market dynamics, though execution risks remain in integrating new technologies and partnerships.
What we're watching
- Robotic Surgery Adoption
- How the CORI SHOULDER system will affect Smith+Nephew's market share in the growing shoulder arthroplasty segment.
- Trauma Portfolio Expansion
- Whether the EVOS PELVIC System and TRIGEN MAX enhancements can drive meaningful revenue growth in the trauma segment.
- ASC Market Strategy
- The pace at which Smith+Nephew can scale its ASC development solutions through new partnerships.